157 related articles for article (PubMed ID: 7893589)
1. S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.
Basci NE; Brosen K; Bozkurt A; Isimer A; Sayal A; Kayaalp SO
Br J Clin Pharmacol; 1994 Nov; 38(5):463-5. PubMed ID: 7893589
[TBL] [Abstract][Full Text] [Related]
2. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study.
Weerasuriya K; Jayakody RL; Smith CA; Wolf CR; Tucker GT; Lennard MS
Br J Clin Pharmacol; 1994 Nov; 38(5):466-70. PubMed ID: 7893590
[TBL] [Abstract][Full Text] [Related]
3. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
Madsen H; Nielsen KK; Brøsen K
Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151
[TBL] [Abstract][Full Text] [Related]
4. Sparteine and mephenytoin oxidation: genetic polymorphisms in east and west Greenland.
Clasen K; Madsen L; Brøsen K; Albøge K; Misfeldt S; Gram LF
Clin Pharmacol Ther; 1991 Jun; 49(6):624-31. PubMed ID: 2060251
[TBL] [Abstract][Full Text] [Related]
5. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
Drøhse A; Bathum L; Brøsen K; Gram LF
Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
[TBL] [Abstract][Full Text] [Related]
6. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.
Alván G; Bechtel P; Iselius L; Gundert-Remy U
Eur J Clin Pharmacol; 1990; 39(6):533-7. PubMed ID: 2151318
[TBL] [Abstract][Full Text] [Related]
7. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.
Sanz EJ; Villén T; Alm C; Bertilsson L
Clin Pharmacol Ther; 1989 May; 45(5):495-9. PubMed ID: 2721104
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians.
Kiivet RA; Svensson JO; Bertilsson L; Sjöqvist F
Pharmacol Toxicol; 1993 Feb; 72(2):113-5. PubMed ID: 8474964
[TBL] [Abstract][Full Text] [Related]
9. [The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs].
Brøsen K
Ugeskr Laeger; 1991 Feb; 153(6):417-22. PubMed ID: 2000644
[TBL] [Abstract][Full Text] [Related]
10. Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.
Llerena A; Valdivielso MJ; Benítez J; Bertilsson L
Pharmacol Toxicol; 1993 Jul; 73(1):46-8. PubMed ID: 8234192
[TBL] [Abstract][Full Text] [Related]
11. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.
Dahl-Puustinen ML; Alm C; Bertilsson L; Christenson I; Ostman J; Thunberg E; Wikström I
Br J Clin Pharmacol; 1990 Sep; 30(3):476-80. PubMed ID: 2121211
[TBL] [Abstract][Full Text] [Related]
12. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
Wedlund PJ; Aslanian WS; McAllister CB; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1984 Dec; 36(6):773-80. PubMed ID: 6499356
[TBL] [Abstract][Full Text] [Related]
13. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.
Inaba T; Jurima M; Nakano M; Kalow W
Clin Pharmacol Ther; 1984 Nov; 36(5):670-6. PubMed ID: 6488688
[TBL] [Abstract][Full Text] [Related]
14. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
[TBL] [Abstract][Full Text] [Related]
15. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
Horai Y; Taga J; Ishizaki T; Ishikawa K
Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
[TBL] [Abstract][Full Text] [Related]
16. Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.
Bozkurt A; Basçi NE; Işimer A; Sayal A; Kayaalp SO
Eur J Drug Metab Pharmacokinet; 1996; 21(4):309-14. PubMed ID: 9074895
[TBL] [Abstract][Full Text] [Related]
17. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
Brøsen K; Gram LF; Kragh-Sørensen P
Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
Sindrup SH; Brøsen K; Hansen MG; Aaes-Jørgensen T; Overø KF; Gram LF
Ther Drug Monit; 1993 Feb; 15(1):11-7. PubMed ID: 8451774
[TBL] [Abstract][Full Text] [Related]
19. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
Nielsen KK; Brøsen K; Hansen MG; Gram LF
Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
[TBL] [Abstract][Full Text] [Related]
20. Sparteine oxidation by the human liver: absence of inhibition by mephenytoin.
Jurima M; Inaba T; Kalow W
Clin Pharmacol Ther; 1984 Mar; 35(3):426-8. PubMed ID: 6697650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
